HUTCHMED (HCM) Competitors

Harmony Biosciences (NASDAQ:HRMY) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.

Does the media refer more to HRMY or HCM?

In the previous week, Harmony Biosciences had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Harmony Biosciences and 3 mentions for HUTCHMED. Harmony Biosciences' average media sentiment score of 1.19 beat HUTCHMED's score of 0.42 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of HRMY or HCM?

84.8% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 22.1% of HUTCHMED shares are owned by institutional investors. 34.7% of Harmony Biosciences shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts recommend HRMY or HCM?

Harmony Biosciences currently has a consensus price target of $62.89, suggesting a potential upside of 74.74%. HUTCHMED has a consensus price target of $16.00, suggesting a potential upside of 30.83%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
HUTCHMED	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community prefer HRMY or HCM?

HUTCHMED received 284 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 66.89% of users gave HUTCHMED an outperform vote while only 46.34% of users gave Harmony Biosciences an outperform vote.

Company	Underperform	Outperform
Harmony Biosciences	Outperform Votes 19 46.34%	Underperform Votes 22 53.66%
HUTCHMED	Outperform Votes 303 66.89%	Underperform Votes 150 33.11%

Is HRMY or HCM more profitable?

Harmony Biosciences has a net margin of 40.19% compared to HUTCHMED's net margin of 0.00%. Harmony Biosciences' return on equity of 49.67% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	40.19%	49.67%	28.11%
HUTCHMED	N/A	N/A	N/A

Which has better valuation & earnings, HRMY or HCM?

Harmony Biosciences has higher revenue and earnings than HUTCHMED.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$437.86 million	4.94	$181.47 million	$3.10	11.63
HUTCHMED	$426.41 million	4.98	-$360.83 million	N/A	N/A

Which has more risk & volatility, HRMY or HCM?

Harmony Biosciences has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Summary

Harmony Biosciences beats HUTCHMED on 12 of the 16 factors compared between the two stocks.